The reagent kit is used in the examination of patients diagnosed with non-small cell lung cancer (NSCLC) to determine indications for targeted therapy with EGFR tyrosine kinase inhibitors and monitor response to them.
The gene expression kit is designed to detect 16 somatic mutations in the BRCA1 and BRCA2 genes.
The gene expression kit is designed to detect 16 germline mutations in the BRCA1 and BRCA2 genes.